Professor Yin Xiaojian discusses tarlatamab in small cell lung cancer: clinical use, access and future development

Professor Yin Xiaojian discusses tarlatamab's clinical use after its approval in China, covering second-line efficacy in SCLC, safety management, payment access and earlier-line exploration. DeLLphi-304 showed tarlatamab extended median OS in second-line patients from 8.3 months with chemotherapy to 13.6 months, reducing death risk by 40% (HR=0.60). The drug received third-line and second-line approvals in April and May 2026, and Fujian's Huiminbao 2026 included it in its high-cost drug reimbursement list.